Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Over the last 12 months, insiders at Vera Therapeutics, Inc. have bought $5M and sold $70.66M worth of Vera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Vera Therapeutics, Inc. have bought $44.26M and sold $24.59M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Katabi Maha (director) — $10M.
The last purchase of 161,290 shares for transaction amount of $5M was made by Katabi Maha (director) on 2024‑01‑30.
2025-01-08 | Sale | PRESIDENT AND CEO | 17,500 0.0275% | $41.74 | $730,535 | -11.51% | ||
2024-12-18 | Sale | PRESIDENT AND CEO | 17,500 0.0289% | $43.07 | $753,680 | -0.60% | ||
2024-12-11 | Sale | PRESIDENT AND CEO | 17,500 0.0277% | $46.94 | $821,523 | -8.78% | ||
2024-11-25 | Sale | PRESIDENT AND CEO | 19,375 0.0313% | $47.98 | $929,560 | -6.81% | ||
2024-11-13 | Sale | PRESIDENT AND CEO | 30,625 0.048% | $49.50 | $1.52M | -6.93% | ||
2024-10-28 | Sale | director | 15,000 0.0323% | $48.03 | $720,493 | 0.00% | ||
2024-10-23 | Sale | PRESIDENT AND CEO | 19,375 0.0351% | $40.39 | $782,610 | 0.00% | ||
2024-10-09 | Sale | PRESIDENT AND CEO | 15,625 0.0239% | $38.24 | $597,568 | +13.15% | ||
2024-09-25 | Sale | PRESIDENT AND CEO | 22,225 0.0419% | $46.02 | $1.02M | -0.77% | ||
2024-09-19 | Sale | director | 13,823 0.0254% | $42.31 | $584,793 | +3.91% | ||
2024-09-18 | Sale | director | 2,653 0.005% | $42.01 | $111,440 | +7.71% | ||
2024-09-11 | Sale | PRESIDENT AND CEO | 15,625 0.0285% | $37.50 | $585,934 | 0.00% | ||
2024-08-28 | Sale | PRESIDENT AND CEO | 30,320 0.0555% | $36.84 | $1.12M | +15.87% | ||
2024-08-21 | Sale | PRESIDENT AND CEO | 14,471 0.0263% | $39.76 | $575,425 | +5.88% | ||
2024-08-14 | Sale | PRESIDENT AND CEO | 15,625 0.03% | $37.56 | $586,927 | 0.00% | ||
2024-05-16 | Sale | SVP, FINANCE, CHIEF ACCT OFFCR | 20,651 0.037% | $42.32 | $873,890 | -4.25% | ||
2024-05-15 | Sale | SVP, FINANCE, CHIEF ACCT OFFCR | 10,186 0.0184% | $42.27 | $430,546 | -5.95% | ||
2024-04-10 | Sale | SVP, FINANCE, CHIEF ACCT OFFCR | 5,714 0.01% | $40.00 | $228,560 | -3.24% | ||
2024-04-03 | Sale | CHIEF FINANCIAL OFFICER | 118,477 0.2156% | $39.58 | $4.69M | +1.54% | ||
2024-03-25 | Sale | director | 340,000 0.6089% | $40.50 | $13.77M | -2.14% |
COMMODORE CAPITAL LP | 10 percent owner | 4400000 6.9485% | $36.94 | 1 | 1 | +20.13% |
Katabi Maha | director | 2793987 4.4123% | $36.94 | 2 | 3 | +57.41% |
Fordyce Marshall | PRESIDENT AND CEO | 143603 0.2268% | $36.94 | 0 | 21 | |
SEIDENBERG BETH C | director | 131553 0.2077% | $36.94 | 19 | 3 | +96.5% |
Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 51206 0.0809% | $36.94 | 2 | 3 | +91.54% |
Grant Sean | CHIEF FINANCIAL OFFICER | 0 0% | $36.94 | 4 | 1 | +32.83% |
Sofinnova Venture Partners X, L.P. | 10 percent owner | 3467156 5.4753% | $36.94 | 3 | 0 | +50.66% |
EMSTER KURT VON | director | 2960231 4.6748% | $36.94 | 2 | 0 | +58.05% |
Abingworth LLP | 10 percent owner | 2960231 4.6748% | $36.94 | 1 | 0 | +57.41% |
Carlyle Group Inc. | 10 percent owner | 2960231 4.6748% | $36.94 | 0 | 1 | |
Carlyle Genesis UK LLC | 2960231 4.6748% | $36.94 | 0 | 1 | ||
ENRIGHT PATRICK G | 1714285 2.7072% | $36.94 | 3 | 0 | +50.66% | |
Longitude Capital Partners IV, LLC | 10 percent owner | 1714285 2.7072% | $36.94 | 3 | 0 | +50.66% |
Curley Joanne | Chief Development Officer | 26962 0.0426% | $36.94 | 0 | 18 | |
Lin Celia | Chief Medical Officer | 11010 0.0174% | $36.94 | 0 | 1 |
Avoro Capital Advisors Llc | $227.03M | 9.63 | 5.26M | New | +$227.03M | 2.72 | |
BlackRock | $143.11M | 6.07 | 3.32M | +20.48% | +$24.32M | <0.01 | |
Commodore Capital, LP | $136.47M | 5.79 | 3.17M | -41.93% | -$98.53M | 0.52 | |
Fidelity Investments | $134.68M | 5.71 | 3.12M | +12.58% | +$15.04M | 0.01 | |
Sofinnova | $120.48M | 5.11 | 2.79M | -19.42% | -$29.03M | 0.25 | |
T. Rowe Price | $103.19M | 4.38 | 2.39M | New | +$103.19M | 0.01 | |
State Street | $101.36M | 4.3 | 2.35M | +7.78% | +$7.32M | <0.01 | |
The Vanguard Group | $92.65M | 3.93 | 2.15M | +31.53% | +$22.21M | <0.01 | |
Eversept Partners LP | $78.64M | 3.33 | 1.82M | -4.75% | -$3.93M | 6.05 | |
Morgan Stanley | $66.27M | 2.81 | 1.54M | +54.48% | +$23.37M | 0.01 | |
Kynam Capital Management Lp | $65.84M | 2.79 | 1.53M | -58.17% | -$91.57M | 0.83 | |
Holocene Advisors, LP | $52.06M | 2.21 | 1.21M | New | +$52.06M | 0.19 | |
Point72 Asset Management | $50.67M | 2.15 | 1.18M | +19.39% | +$8.23M | 0.07 | |
Geode Capital Management | $41.46M | 1.76 | 961,309 | +22.82% | +$7.7M | <0.01 | |
Woodline Partners LP | $40.84M | 1.73 | 947,097 | -62.22% | -$67.27M | 0.35 | |
Adage Capital Partners Gp L L C | $36.1M | 1.53 | 837,195 | New | +$36.1M | 0.07 | |
Altium Capital Management Lp | $30.62M | 1.3 | 710,000 | +15.45% | +$4.1M | 3.59 | |
OrbiMed | $29.14M | 1.24 | 675,872 | -55.48% | -$36.32M | 0.23 | |
Polar Capital | $29.11M | 1.23 | 675,000 | -6.9% | -$2.16M | 0.16 | |
Samlyn Capital, LLC | $27.83M | 1.18 | 645,501 | New | +$27.83M | 0.49 | |
Deutsche Bank | $27.47M | 1.16 | 636,994 | +0.52% | +$142,684.08 | 0.01 | |
D. E. Shaw & Co. | $25.92M | 1.1 | 601,036 | +186.15% | +$16.86M | 0.03 | |
Readystate Asset Management Lp | $25.62M | 1.09 | 594,091 | New | +$25.62M | 1.44 | |
Logos Global Management Lp | $24.79M | 1.05 | 575,000 | New | +$24.79M | 2.68 | |
Goldman Sachs | $24.14M | 1.02 | 559,790 | -13.78% | -$3.86M | <0.01 | |
Artal Group S A | $21.82M | 0.93 | 506,019 | New | +$21.82M | 0.1 | |
Marshall Wace | $20.72M | 0.88 | 480,519 | New | +$20.72M | 0.02 | |
Affinity Asset Advisors | $20.27M | 0.86 | 470,000 | New | +$20.27M | 0.31 | |
Voloridge Investment Management, LLC | $19.27M | 0.82 | 446,905 | +2,566.34% | +$18.55M | 0.07 | |
First Light Asset Management | $18.81M | 0.8 | 436,133 | New | +$18.81M | 1.58 | |
Avidity Partners Management Lp | $16.54M | 0.7 | 383,500 | New | +$16.54M | 0.63 | |
Northern Trust | $16.06M | 0.68 | 372,454 | +15.73% | +$2.18M | <0.01 | |
Integral Health Asset Management Llc | $15.52M | 0.66 | 360,000 | New | +$15.52M | 1.56 | |
Schroder Investment Management Group | $15.16M | 0.64 | 351,653 | -68.35% | -$32.74M | 0.02 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $14.71M | 0.62 | 341,168 | New | +$14.71M | 0.38 | |
Charles Schwab | $14.59M | 0.62 | 338,425 | +21.75% | +$2.61M | <0.01 | |
JPMorgan Chase | $14.47M | 0.61 | 335,564 | +970.55% | +$13.12M | <0.01 | |
Invesco | $13.26M | 0.56 | 307,610 | +13.78% | +$1.61M | <0.01 | |
AXA | $11.73M | 0.5 | 272,078 | -28.9% | -$4.77M | 0.04 | |
Driehaus Capital Management LLC | $11.09M | 0.47 | 257,257 | +276.62% | +$8.15M | 0.11 | |
Alphabet | $10.4M | 0.44 | 241,264 | -20% | -$2.6M | 0.09 | |
Lord Abbett | $9.73M | 0.41 | 225,581 | New | +$9.73M | 0.03 | |
Bank of America | $8.63M | 0.37 | 200,152 | +420.11% | +$6.97M | <0.01 | |
Rafferty Asset Management Llc | $7.54M | 0.32 | 174,783 | +2.36% | +$173,558.00 | 0.02 | |
BNY Mellon | $6.7M | 0.28 | 155,468 | +18.39% | +$1.04M | <0.01 | |
PLATINUM INVESTMENT MANAGEMENT LTD | $6.64M | 0.28 | 153,932 | -23.15% | -$2M | 0.09 | |
Citigroup | $6.58M | 0.28 | 152,568 | +117.01% | +$3.55M | 0.01 | |
Nuveen | $6.33M | 0.27 | 146,823 | -25.92% | -$2.21M | <0.01 | |
Two Sigma | $6.1M | 0.26 | 141,350 | +39.55% | +$1.73M | 0.01 | |
Wellington Management Company | $5.64M | 0.24 | 130,794 | New | +$5.64M | <0.01 |